Carlsmed (CARL) Q3 2026 earnings review
Carlsmed sales growth speeds up, while overhead and severance weigh
Carlsmed, a maker of custom 3D-printed spinal implants, sped up its sales growth while narrowing its underlying operating loss. Third-quarter revenue rose 65% to $21.6 million, outpacing what the prior second-half plan pointed to, as sales and marketing costs took a smaller share of revenue. Chief executive Mike Cordonnier raised the full-year outlook for a third time, though by our math the new target leaves fourth-quarter growth slowing to 48%.
| Revenue | $21.6M +65% from a year ago |
|---|---|
| Gross margin | 77.3% 75.9% a year ago |
| Operating loss excluding one-offs and stock pay (Adjusted EBITDA) | -$7.3M -$8.2M a year ago |
| Full-year revenue outlook | Raised $3M middle of the range: 56% growth |
⚖️ Verdict: 🟢 Bullish
The story got better because top-line growth accelerated after two slower quarters and gross margin held above 77%. That combination showed that adding lower-priced neck implants and onboarding new doctors did not drag down overall sales per surgeon or manufacturing margins. One caution: administrative overhead more than doubled on executive turnover and legal costs, draining another $9 million from the cash balance.
The question now is whether the fourth-quarter slowdown implied by the outlook is simply management caution or a real pause in lower-back surgeries as neck implants lap their December launch. If management is being cautious, fourth-quarter sales will beat the implied $22 million mark; if lower-back demand is cooling, sales will rise barely 4% from the third quarter. Next quarter's results and the 2027 outlook will settle it.
🐂 Bull Case
Revenue Growth Accelerated and Cleared the Bar
Carlsmed makes custom 3D-printed spinal implants designed with artificial intelligence. After two quarters of slowing percentage gains, sales growth sped up in the third quarter. Revenue reached $21.6 million, up 64.9% from a year ago and 13.8% above the second quarter.
Chief executive Mike Cordonnier credited the result to execution "as we grew our surgeon user base by more than 60% over the prior year". Because revenue grew faster than that 60% floor, average sales per trained doctor held up better than the prior outlook suggested. Management raised its full-year sales plan by $3 million at the middle of the range, to between $78 million and $80 million.
What to watch: the exact percentage of trained surgeons in the quarterly filing. If the filing reports user growth near last quarter's 67% mark, output per doctor still dipped slightly as new doctors joined.
Lower Sales Costs Narrowed the Operating Loss
As surgeons order more implants for both lower-back and neck procedures, Carlsmed is getting more sales out of its commercial team. Gross margin — the share of sales left after the cost of making the implants — rose to 77.3%, beating the 77% floor management set for the second half.
- Sales and marketing expense: 60.3% of revenue, down 13.2 percentage points from a year ago by our math
- Research and development expense: 29.6% of revenue, down 4.4 percentage points
- Operating loss excluding one-offs and stock pay (Adjusted EBITDA): $7.3 million, or 33.7% of sales, compared with 63.1% a year ago
What to watch: fourth-quarter gross margin against the 77% mark. Keeping the margin above 77% while neck implants grow will show that manufacturing savings outweigh the lower price of neck devices.
Medicare Boosts Pay and Product Line Expands
Two October milestones widen the market for aprevo, Carlsmed's family of custom spinal fusion implants. First, the US Medicare agency's hospital payment rule took effect on October 1, increasing reimbursement for inpatient lower-back surgeries using aprevo. Higher hospital payments make it easier for hospital purchasing committees to approve the device.
Second, the medical device maker launched its aprevo Lumbar Bi-lateral Posterior System in October, hitting its fourth-quarter target early. The company estimates this system "addresses approximately 30,000 U.S. lumbar fusion procedures annually", allowing surgeons to treat patients from the back of the spine.
What to watch: whether the corra custom neck plate launches on schedule by December. Completing that release will finish the 2026 product lineup and help raise the average price of neck procedures.
🐻 Bear Case
Overhead Costs and Cash Drain Keep Rising
"Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027," Cordonnier said. While Carlsmed carries very little inventory, running the business still consumes substantial cash.
Total cash and marketable securities dropped by $9.0 million in the quarter to $80.3 million, and have fallen by $29.6 million over the first nine months of 2026 by our math. General and administrative overhead more than doubled to $10.0 million, jumping 8.8 percentage points to 46.3% of revenue.
That overhead bill included $2.8 million for "executive transition costs and the expected resolution of certain legal matters", while employee stock pay more than tripled to $2.5 million. Even stripping out the $2.8 million in one-off charges, administrative spending grew 45.6% from a year ago, lifting the GAAP net loss by 43.6% to $12.2 million.
What to watch: quarterly cash burn in the fourth quarter. If cash falls by another $8 million or more after executive severance clears, management will face pressure to set a firm breakeven date.
Fourth-Quarter Plan Points to a Sharp Slowdown
Carlsmed has raised its 2026 revenue target every quarter this year, yet the new $78 million to $80 million range leaves little room for fourth-quarter growth. After generating $56.6 million in the first nine months, the middle of the full-year outlook leaves $22.4 million for the fourth quarter by our math.
That implied $22.4 million figure represents 47.6% growth from a year ago, down from 64.9% in the third quarter. It also implies just 3.9% growth from the third quarter, even though the fourth quarter is typically busy for elective spine surgeries and includes the new lower-back implant launch.
What to watch: fourth-quarter revenue against the $23.4 million top end of the implied range. A result above $23.4 million will show management was simply cautious rather than seeing a slowdown in lower-back procedures.
Risks this quarter didn't answer
Several standing concerns about product mix, doctor usage and competition received no new numbers in the earnings release.
- Neck implant revenue share and lower-back growth: not in the release after reaching 10% in the second quarter; the conference call or filing must show whether neck procedures hit the 11% to 12% second-half plan and how fast the core lower-back business grew.
- Surgeon count and procedures per doctor: management gave only a "more than 60%" growth floor rather than an exact doctor count or procedure volume.
- Rival custom implants and hospital approvals: the release did not address competing devices or how many hospitals have approved the new Medicare payment codes.
👓 Other Themes
Leadership Overhaul Adds Three New C-Suite Executives
Carlsmed reshaped its senior management team during the quarter, recording $2.4 million in executive severance and transition expenses. The company appointed Rich Heppenstall as chief financial officer, promoted Jeff Bertolini to chief operating officer, and hired Tony Jarc as chief product and artificial intelligence officer to oversee product development.
💲 Other KPIs
Uncollected customer bills rose 22.6% from last quarter, outpacing the 13.8% rise in revenue. However, the reserve for unpaid bills dropped to $1.5 million from $2.8 million in June, falling from 16.9% of total bills to 8.1% by our math, likely reflecting write-offs or resolved hospital accounts.
Stock on hand grew 31.3% from the second quarter and is up 61.9% since the end of 2025. Because the spine specialist prints its implants to order for each patient, total inventory remains small at less than two months of cost of sales, even ahead of fourth-quarter product launches.
The average share count rose 29.5% from a year ago because the third quarter of 2025 only partially reflected the July 2025 initial public offering. Compared with the second quarter of 2026, the share count crept up 0.4% from employee stock plans.
🔮 Guidance
Raised. The middle of the full-year plan moved up by $3.0 million to $79.0 million, pointing to 56.4% growth for the year. By our math, that leaves $22.4 million for the fourth quarter, or 47.6% growth from a year ago versus 64.9% in the third quarter. It is the third raise this year, and the largest: +$2.0M, +$1.5M, and now +$3.0M.
❓ Key Questions
What share of third-quarter sales came from neck implants?
Neck devices made up about 10% of sales in the second quarter, and management planned for 11% to 12% in the second half. Without that figure, investors cannot tell whether core lower-back sales sped up or slowed down.
Why did the reserve for unpaid hospital bills drop?
The allowance for credit losses fell from $2.8 million in June to $1.5 million in September while unpaid bills rose by $3.1 million. Management has not said whether hospitals paid old bills or Carlsmed wrote them off.
What legal dispute triggered the $450,000 settlement charge?
Carlsmed booked $450,000 for expected legal settlements this quarter after noting rising intellectual-property and ordinary-course legal fees last quarter. Investors need to know if a patent dispute is now resolved.
When will the company reach cash-flow breakeven?
Cash and marketable securities fell by $9.0 million this quarter to $80.3 million, and total operating expenses grew 54.9% from a year ago. Management still has not named the revenue level needed to stop burning cash.